62 related articles for article (PubMed ID: 1492231)
21. Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.
Triozzi PL; Tucker F; Benzies T; Balcerzak SP
Bone Marrow Transplant; 1996 Jul; 18(1):47-52. PubMed ID: 8831995
[TBL] [Abstract][Full Text] [Related]
22. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies.
Vose JM; Bierman PJ; Kessinger A; Coccia PF; Anderson J; Oldham FB; Epstein C; Armitage JO
Bone Marrow Transplant; 1991 Feb; 7(2):139-43. PubMed ID: 1675592
[TBL] [Abstract][Full Text] [Related]
23. Platelet support and the use of cytokines.
Bishop JF
Stem Cells; 1994 Jul; 12(4):370-7. PubMed ID: 7524892
[TBL] [Abstract][Full Text] [Related]
24. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
Shaffer DW; Smith LS; Burris HA; Clark GM; Eckardt JR; Fields SM; Weiss GR; Rinaldi DA; Bowen KJ; Kuhn JG
Cancer Res; 1993 Dec; 53(24):5929-33. PubMed ID: 8261405
[TBL] [Abstract][Full Text] [Related]
25. Hematopoietic protection by dexamethasone or granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients treated with carboplatin and ifosfamide.
Rinehart J; Keville L; Neidhart J; Wong L; DiNunno L; Kinney P; Aberle M; Tadlock L; Cloud G
Am J Clin Oncol; 2003 Oct; 26(5):448-58. PubMed ID: 14528069
[TBL] [Abstract][Full Text] [Related]
26. [Granulocyte-macrophage colony-stimulating factor in the treatment of secondary bone marrow suppression in patients with lymphoma. Preliminary report].
Avilés A; Díaz-Maqueo JC; Talavera A; García EL
Arch Invest Med (Mex); 1990; 21(2):133-7. PubMed ID: 2103701
[TBL] [Abstract][Full Text] [Related]
27. Future uses of granulocyte-macrophage colony-stimulating factor (GM-CSF).
Jones TC
Stem Cells; 1994; 12 Suppl 1():229-39; discussion 239-40. PubMed ID: 7696962
[TBL] [Abstract][Full Text] [Related]
28. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
Ohnoshi T; Ueoka H; Kodani T; Kamei H; Kimura I
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):911-8. PubMed ID: 1693062
[TBL] [Abstract][Full Text] [Related]
29. Differential effect of continuous versus cyclic maintenance chemotherapy on cytokine-induced myeloid colony growth.
Ridgway D; Borzy MS
Hematol Pathol; 1990; 4(2):87-92. PubMed ID: 2197267
[TBL] [Abstract][Full Text] [Related]
30. Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor.
Broxmeyer HE; Cooper S; Williams DE; Hangoc G; Gutterman JU; Vadhan-Raj S
Exp Hematol; 1988 Aug; 16(7):594-602. PubMed ID: 3260558
[TBL] [Abstract][Full Text] [Related]
31. Treatment of drug-induced agranulocytosis with recombinant GM-CSF.
Palmblad J; Jonson B; Kanerud L
J Intern Med; 1990 Nov; 228(5):537-9. PubMed ID: 1979344
[TBL] [Abstract][Full Text] [Related]
32. Rapid neutrophil recovery from acquired agranulocytosis by recombinant human granulocyte-macrophage colony-stimulating factor in an intensive care patient.
Weiss M; Gross-Weege W; Wernet P
Crit Care Med; 1992 Oct; 20(10):1490-1. PubMed ID: 1395674
[No Abstract] [Full Text] [Related]
33. [Betaleukin (human recombinant interleukin-1 beta)--a new effective leukopoiesis stimulant and protector in the combined chemotherapy of malignant tumors].
Gershanovich ML; Filatova LV; Ketlinskiĭ SA; Simbirtsev AS
Vopr Onkol; 2000; 46(3):354-60. PubMed ID: 10976287
[No Abstract] [Full Text] [Related]
34. [Thrombocytopenias and granulocytopenias].
Diebold W
Kinderkrankenschwester; 1993 Mar; 12(3):105-6. PubMed ID: 8489939
[No Abstract] [Full Text] [Related]
35. Use of granulocyte-macrophage colony stimulating factor for treatment of drug-induced agranulocytosis.
Wallach FR; Zirn J; Murray HW; Tepler J; Luger NM
Rev Infect Dis; 1991; 13(3):523. PubMed ID: 1866563
[No Abstract] [Full Text] [Related]
36. Idiosyncratic drug-induced haematological abnormalities. Incidence, pathogenesis, management and avoidance.
Patton WN; Duffull SB
Drug Saf; 1994 Dec; 11(6):445-62. PubMed ID: 7727054
[TBL] [Abstract][Full Text] [Related]
37. Granulocyte-macrophage colony-stimulating factor with dose-intensified treatment of cancer.
Clark DA; Neidhart JA
Semin Hematol; 1992 Oct; 29(4 Suppl 3):27-32. PubMed ID: 1492231
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte-macrophage colony-stimulating factor given before dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).
Holdsworth MT; Roon R; Ferguson J; Martinez L; Stidley CA; Neidhart JA
Biotechnol Ther; 1993; 4(3-4):183-95. PubMed ID: 8292969
[TBL] [Abstract][Full Text] [Related]
39. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
40. The role of granulocyte-macrophage colony-stimulating factor in the treatment of germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Rüther U; Metzner B; Illiger HJ; Clemm C; Siegert W; Link H; Ostermann H; Schmoll HJ
Semin Oncol; 1994 Dec; 21(6 Suppl 16):57-63. PubMed ID: 7801148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
